Tumor-Infiltrating Lymphocytes Therapy Now Available for Treating Unresectable or Metastatic Melanoma
When the FDA granted accelerated approval of tumor-infiltrating lymphocyte (TIL) treatment with lifileucel for patients with metastatic melanoma, Cleveland Clinic Cancer Institute was one of 23 select Early-Authorized Treatment Centers across the country approved to administer this new form of cellular therapy. This is the first-of-its-kind treatment for solid tumor malignancy.